EISAI CO LTD (EII BE) stock market data APIs
€30.3229
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
EISAI CO LTD Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EII.BE.
Prev. Close
30.3229
Open
30.3229
High
30.3229
Low
30.3229
52 wk Range
21.74-36.0698
Market Cap
15 022 M
EPS
39.18
Dividends (Yield)
1.2903
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EISAI CO LTD data using free add-ons & libraries
Get EISAI CO LTD Fundamental Data
EISAI CO LTD Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: 32.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EISAI CO LTD News
New
8MM Alzheimer's Disease Market Drug Forecast and Market Analysis 2025-2033 | Eisai, Biogen, and Lilly to Lead, Novel Late-stage Pipeline Drugs Will Be a Key Driver, Opportunities in Unmet Needs
Company Logo Alzheimer’s market growth opportunities lie in developing disease-modifying treatments and anti-Aβ monoclonal antibodies, driven by unmet needs in AD therapies. The US and China domin...
Assessing Eisai (TSE:4523) Valuation as Investor Interest Builds Despite Lack of Major News
If you’ve been watching Eisai (TSE:4523) lately, you might be wondering what’s driving the conversation around its stock price. The latest move has caught the eye of investors, not necessarily bec...
Do Positive E2086 Data Bolster Eisai’s (TSE:4523) Neurology Pipeline Credibility for Long-Term Growth?
Eisai Co., Ltd. recently presented results from a Phase Ib clinical trial showing that its novel selective orexin 2 receptor agonist, E2086, significantly improved daytime wakefulness in people with n...
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1 TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced t...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
